Mesa Laboratories
Market Cap
US$1.4b
Last Updated
2021/02/28 23:45 UTC
Data Sources
Company Financials +
Executive Summary
Mesa Laboratories, Inc. designs, manufactures, and markets quality control instruments and disposable products in the United States, Canada, Europe, and Japan. More Details
Rewards
Risk Analysis
Snowflake Analysis
Excellent balance sheet with moderate growth potential.
Similar Companies
Share Price & News
How has Mesa Laboratories's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MLAB is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: MLAB's weekly volatility (4%) has been stable over the past year.
Market Performance
7 Day Return
-1.6%
MLAB
-2.4%
US Medical Equipment
-3.6%
US Market
1 Year Return
13.6%
MLAB
35.8%
US Medical Equipment
36.5%
US Market
Return vs Industry: MLAB underperformed the US Medical Equipment industry which returned 33.8% over the past year.
Return vs Market: MLAB underperformed the US Market which returned 36.4% over the past year.
Shareholder returns
| MLAB | Industry | Market | |
|---|---|---|---|
| 7 Day | -1.6% | -2.4% | -3.6% |
| 30 Day | -1.9% | 0.07% | 2.7% |
| 90 Day | 0.06% | 6.5% | 7.5% |
| 1 Year | 13.9%13.6% | 36.9%35.8% | 39.5%36.5% |
| 3 Year | 113.3%111.5% | 76.7%72.4% | 53.5%43.6% |
| 5 Year | 220.6%214.7% | 155.5%136.8% | 117.5%93.2% |
Long-Term Price Volatility Vs. Market
How volatile is Mesa Laboratories's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 days ago | Simply Wall St
Have Mesa Laboratories, Inc. (NASDAQ:MLAB) Insiders Been Selling Their Stock?3 weeks ago | Simply Wall St
How Much Does Mesa Laboratories' (NASDAQ:MLAB) CEO Make?1 month ago | Simply Wall St
Has Mesa Laboratories (NASDAQ:MLAB) Got What It Takes To Become A Multi-Bagger?Valuation
Is Mesa Laboratories undervalued compared to its fair value and its price relative to the market?
3.38x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: MLAB ($271.91) is trading above our estimate of fair value ($168.75)
Significantly Below Fair Value: MLAB is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: MLAB is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: MLAB is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MLAB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MLAB is good value based on its PB Ratio (3.4x) compared to the US Medical Equipment industry average (5.1x).
Next Steps
Future Growth
How is Mesa Laboratories forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
111.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MLAB is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: MLAB is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MLAB's is expected to become profitable in the next 3 years.
Revenue vs Market: MLAB's revenue (8% per year) is forecast to grow slower than the US market (10.4% per year).
High Growth Revenue: MLAB's revenue (8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MLAB's Return on Equity is forecast to be low in 3 years time (7.2%).
Next Steps
Past Performance
How has Mesa Laboratories performed over the past 5 years?
-34.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MLAB is currently unprofitable.
Growing Profit Margin: MLAB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MLAB is unprofitable, and losses have increased over the past 5 years at a rate of 34.2% per year.
Accelerating Growth: Unable to compare MLAB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MLAB is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (5.7%).
Return on Equity
High ROE: MLAB has a negative Return on Equity (-0.64%), as it is currently unprofitable.
Next Steps
Financial Health
How is Mesa Laboratories's financial position?
Financial Position Analysis
Short Term Liabilities: MLAB's short term assets ($295.3M) exceed its short term liabilities ($27.8M).
Long Term Liabilities: MLAB's short term assets ($295.3M) exceed its long term liabilities ($181.1M).
Debt to Equity History and Analysis
Debt Level: MLAB's debt to equity ratio (35%) is considered satisfactory.
Reducing Debt: MLAB's debt to equity ratio has reduced from 58.2% to 35% over the past 5 years.
Debt Coverage: MLAB's debt is well covered by operating cash flow (22.1%).
Interest Coverage: MLAB is unprofitable, therefore interest payments are not well covered by earnings.
Balance Sheet
Next Steps
Dividend
What is Mesa Laboratories's current dividend yield, its reliability and sustainability?
0.24%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: MLAB's dividend (0.24%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.34%).
High Dividend: MLAB's dividend (0.24%) is low compared to the top 25% of dividend payers in the US market (3.77%).
Stability and Growth of Payments
Stable Dividend: MLAB is not paying a notable dividend for the US market, therefore no need to check if payments are stable.
Growing Dividend: MLAB is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: MLAB is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MLAB's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.3yrs
Average management tenure
CEO
Gary Owens (52 yo)
3.42yrs
Tenure
US$3,485,969
Compensation
Mr. Gary M. Owens has been Chief Executive Officer, President and Director of Mesa Laboratories, Inc. since September 1, 2017. Mr. Owens joined as Chief Operating Officer in March 2017. Mr. Owens served as...
CEO Compensation Analysis
Compensation vs Market: Gary's total compensation ($USD3.49M) is about average for companies of similar size in the US market ($USD3.68M).
Compensation vs Earnings: Gary's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 3.42yrs | US$3.49m | 0.19% $ 2.7m | |
| CFO, Chief Accounting Officer & Treasurer | 8.33yrs | US$1.13m | 0.085% $ 1.2m | |
| Senior Vice President of Commercial Operations | 3.25yrs | US$898.97k | 0.016% $ 228.4k | |
| Senior Vice President of Continuous Improvement | 3.08yrs | US$700.88k | 0.0045% $ 63.1k | |
| Senior Director of Operations | no data | no data | no data | |
| VP of Legal | no data | no data | no data | |
| Vice President of Human Resources | no data | no data | no data | |
| Senior Vice President of Operations | no data | US$281.45k | no data | |
| Senior Vice President of Operations | no data | US$280.56k | no data |
3.3yrs
Average Tenure
53.5yo
Average Age
Experienced Management: MLAB's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 3.42yrs | US$3.49m | 0.19% $ 2.7m | |
| Independent Director | 10.33yrs | US$174.87k | 0.046% $ 639.0k | |
| Independent Director | 12yrs | US$174.87k | 0.64% $ 8.9m | |
| Chairman of the Board | 3.42yrs | US$196.87k | 1.15% $ 16.1m | |
| Independent Director | 0.75yr | no data | 0.0050% $ 69.1k | |
| Independent Director | 5.83yrs | US$174.87k | 1.4% $ 19.5m | |
| Independent Director | 1.92yrs | US$164.87k | 0.013% $ 186.6k |
3.4yrs
Average Tenure
52yo
Average Age
Experienced Board: MLAB's board of directors are considered experienced (3.4 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: MLAB insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.4%.
Top Shareholders
Company Information
Mesa Laboratories, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Mesa Laboratories, Inc.
- Ticker: MLAB
- Exchange: NasdaqGS
- Founded: 1982
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$1.395b
- Shares outstanding: 5.13m
- Website: https://www.mesalabs.com
Number of Employees
Location
- Mesa Laboratories, Inc.
- 12100 West Sixth Avenue
- Lakewood
- Colorado
- 80228
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| MLAB | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Feb 1984 |
| MLI | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Feb 1984 |
Biography
Mesa Laboratories, Inc. designs, manufactures, and markets quality control instruments and disposable products in the United States, Canada, Europe, and Japan. The company’s Sterilization and Disinfection ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/02/28 23:45 |
| End of Day Share Price | 2021/02/26 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.